Skip to main content
Erschienen in: Tumor Biology 6/2012

01.12.2012 | Research Article

MMP1-1607 1G/2G polymorphism and lung cancer risk: a meta-analysis

verfasst von: Xu-Yang Xiao, Xiao-Dong Wang, Dong-Yu Zang

Erschienen in: Tumor Biology | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Abstract

Matrix metalloproteinase-1 (MMP-1) plays an important role in the breakdown of extracellular matrix and mediates pathways of apoptosis, angiogenesis, and immunity. It has been demonstrated that MMP-1 overexpression is associated with tumor initiation, invasion, and metastasis. Many studies have investigated the association between MMP1-1607 1G/2G polymorphism and lung cancer risk, but the impact of MMP1-1607 1G/2G polymorphism on lung cancer is unclear owing to the obvious inconsistence among those studies. This study aimed to quantify the strength of the association between MMP1-1607 1G/2G polymorphism and lung cancer risk. We searched the PubMed, Embase, and Wanfang databases for studies on the association between MMP1-1607 1G/2G polymorphism and risk of lung cancer. We estimated summary odds ratio (OR) with its corresponding 95 % confidence interval (95%CI) to assess the association. Overall, MMP1-1607 1G/2G polymorphism was associated with increased risk of lung cancer under four genetic models (OR2G versus 1G = 1.21, 95 %CI 1.06–1.37; OR2G2G versus 1G1G = 1.36, 95%CI 1.09–1.70; OR2G2G versus 2G1G+1G1G = 1.33, 95 %CI 1.10–1.61; and OR2G2G+2G1G versus 1G1G = 1.15, 95 %CI 1.04–1.27). Meta-analyses of studies with high quality showed that MMP1-1607 1G/2G polymorphism was still associated with lung cancer risk under those four genetic models. Subgroup analyses by ethnicity and sensitivity analyses further identified the significant association in East Asians. No evidence of publication bias was observed. Meta-analyses of available data show a significant association between MMP1-1607 1G/2G polymorphism and lung cancer risk.
Literatur
1.
Zurück zum Zitat Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef
2.
Zurück zum Zitat Papagiannis A. Multidisciplinary management of lung cancer. N Engl J Med. 2004;350:2008–10.PubMedCrossRef Papagiannis A. Multidisciplinary management of lung cancer. N Engl J Med. 2004;350:2008–10.PubMedCrossRef
4.
Zurück zum Zitat Brennan P, Hainaut P, Boffetta P. Genetics of lung-cancer susceptibility. Lancet Oncol. 2011;12:399–408.PubMedCrossRef Brennan P, Hainaut P, Boffetta P. Genetics of lung-cancer susceptibility. Lancet Oncol. 2011;12:399–408.PubMedCrossRef
5.
Zurück zum Zitat Steliga MA, Dresler CM. Epidemiology of lung cancer: smoking, secondhand smoke, and genetics. Surg Oncol Clin N Am. 2011;20:605–18.PubMedCrossRef Steliga MA, Dresler CM. Epidemiology of lung cancer: smoking, secondhand smoke, and genetics. Surg Oncol Clin N Am. 2011;20:605–18.PubMedCrossRef
6.
Zurück zum Zitat Yokota J, Shiraishi K, Kohno T. Genetic basis for susceptibility to lung cancer: recent progress and future directions. Adv Cancer Res. 2010;109:51–72.PubMedCrossRef Yokota J, Shiraishi K, Kohno T. Genetic basis for susceptibility to lung cancer: recent progress and future directions. Adv Cancer Res. 2010;109:51–72.PubMedCrossRef
7.
Zurück zum Zitat Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141:52–67.PubMedCrossRef Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141:52–67.PubMedCrossRef
8.
Zurück zum Zitat Attia J, Thakkinstian A, D'Este C. Meta-analyses of molecular association studies: methodologic lessons for genetic epidemiology. J Clin Epidemiol. 2003;56:297–303.PubMedCrossRef Attia J, Thakkinstian A, D'Este C. Meta-analyses of molecular association studies: methodologic lessons for genetic epidemiology. J Clin Epidemiol. 2003;56:297–303.PubMedCrossRef
9.
Zurück zum Zitat Petitti DB, Contreras R, Ziel FH, Dudl J, Domurat ES, Hyatt JA. Evaluation of the effect of performance monitoring and feedback on care process, utilization, and outcome. Diabetes Care. 2000;23:192–6.PubMedCrossRef Petitti DB, Contreras R, Ziel FH, Dudl J, Domurat ES, Hyatt JA. Evaluation of the effect of performance monitoring and feedback on care process, utilization, and outcome. Diabetes Care. 2000;23:192–6.PubMedCrossRef
10.
Zurück zum Zitat Sotiriadis A, Makrigiannakis A, Stefos T, Paraskevaidis E, Kalantaridou SN. Fibrinolytic defects and recurrent miscarriage: a systematic review and meta-analysis. Obstet Gynecol. 2007;109:1146–55.PubMedCrossRef Sotiriadis A, Makrigiannakis A, Stefos T, Paraskevaidis E, Kalantaridou SN. Fibrinolytic defects and recurrent miscarriage: a systematic review and meta-analysis. Obstet Gynecol. 2007;109:1146–55.PubMedCrossRef
11.
Zurück zum Zitat Su MT, Lin SH, Chen YC. Genetic association studies of angiogenesis- and vasoconstriction-related genes in women with recurrent pregnancy loss: a systematic review and meta-analysis. Hum Reprod Update. 2011;17:803–12.PubMedCrossRef Su MT, Lin SH, Chen YC. Genetic association studies of angiogenesis- and vasoconstriction-related genes in women with recurrent pregnancy loss: a systematic review and meta-analysis. Hum Reprod Update. 2011;17:803–12.PubMedCrossRef
12.
Zurück zum Zitat Salanti G, Amountza G, Ntzani EE, Ioannidis JP. Hardy–Weinberg equilibrium in genetic association studies: an empirical evaluation of reporting, deviations, and power. Eur J Hum Genet. 2005;13:840–8.PubMedCrossRef Salanti G, Amountza G, Ntzani EE, Ioannidis JP. Hardy–Weinberg equilibrium in genetic association studies: an empirical evaluation of reporting, deviations, and power. Eur J Hum Genet. 2005;13:840–8.PubMedCrossRef
13.
Zurück zum Zitat Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Canc Inst. 1959;22:719–48. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Canc Inst. 1959;22:719–48.
14.
Zurück zum Zitat DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRef DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRef
15.
Zurück zum Zitat Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRef Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRef
16.
Zurück zum Zitat Cochran WG. The comparison of percentages in matched samples. Biometrika. 1950;37:256–66.PubMed Cochran WG. The comparison of percentages in matched samples. Biometrika. 1950;37:256–66.PubMed
17.
Zurück zum Zitat Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med. 2002;21:1559–73.PubMedCrossRef Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med. 2002;21:1559–73.PubMedCrossRef
18.
Zurück zum Zitat Tobias A. Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull. 1999;8:15–7. Tobias A. Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull. 1999;8:15–7.
19.
Zurück zum Zitat Burchard EG, Ziv E, Coyle N, Gomez SL, Tang H, Karter AJ, Mountain JL, Perez-Stable EJ, Sheppard D, Risch N. The importance of race and ethnic background in biomedical research and clinical practice. N Engl J Med. 2003;348:1170–5.PubMedCrossRef Burchard EG, Ziv E, Coyle N, Gomez SL, Tang H, Karter AJ, Mountain JL, Perez-Stable EJ, Sheppard D, Risch N. The importance of race and ethnic background in biomedical research and clinical practice. N Engl J Med. 2003;348:1170–5.PubMedCrossRef
20.
Zurück zum Zitat Bhopal R. Glossary of terms relating to ethnicity and race: for reflection and debate. J Epidemiol Commun Health. 2004;58:441–5.CrossRef Bhopal R. Glossary of terms relating to ethnicity and race: for reflection and debate. J Epidemiol Commun Health. 2004;58:441–5.CrossRef
21.
Zurück zum Zitat Stuck AE, Rubenstein LZ, Wieland D. Bias in meta-analysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ. 1998;316(469):470–1. Stuck AE, Rubenstein LZ, Wieland D. Bias in meta-analysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ. 1998;316(469):470–1.
22.
Zurück zum Zitat Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRef Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRef
23.
Zurück zum Zitat Liu L, Wu J, Wu C, Wang Y, Zhong R, Zhang X, Tan W, Nie S, Miao X, Lin D. A functional polymorphism (−1607 1G– > 2G) in the matrix metalloproteinase-1 promoter is associated with development and progression of lung cancer. Cancer. 2011;117:5172–81.PubMedCrossRef Liu L, Wu J, Wu C, Wang Y, Zhong R, Zhang X, Tan W, Nie S, Miao X, Lin D. A functional polymorphism (−1607 1G– > 2G) in the matrix metalloproteinase-1 promoter is associated with development and progression of lung cancer. Cancer. 2011;117:5172–81.PubMedCrossRef
24.
Zurück zum Zitat Hart K, Landvik NE, Lind H, Skaug V, Haugen A, Zienolddiny S. A combination of functional polymorphisms in the casp8, mmp1, il10 and seps1 genes affects risk of non-small cell lung cancer. Lung Canc-J IASLC. 2011;71:123–9.CrossRef Hart K, Landvik NE, Lind H, Skaug V, Haugen A, Zienolddiny S. A combination of functional polymorphisms in the casp8, mmp1, il10 and seps1 genes affects risk of non-small cell lung cancer. Lung Canc-J IASLC. 2011;71:123–9.CrossRef
25.
Zurück zum Zitat Gonzalez-Arriaga P, Lopez-Cima MF, Fernandez-Somoano A, Pascual T, Marron MG, Puente XS, Tardon A. Polymorphism +17 c/g in matrix metalloprotease mmp8 decreases lung cancer risk. BMC Canc. 2008;8:378.CrossRef Gonzalez-Arriaga P, Lopez-Cima MF, Fernandez-Somoano A, Pascual T, Marron MG, Puente XS, Tardon A. Polymorphism +17 c/g in matrix metalloprotease mmp8 decreases lung cancer risk. BMC Canc. 2008;8:378.CrossRef
26.
Zurück zum Zitat Wei WQ, Liang XQ, Wen XP. The association of mmp-1-1607(1G–2G) single nucleotide polymorphism with the susceptibility to non-small cell lung carcinoma in Guizhou Han nationality. J Guiyang Med College. 2007;32:267–72 [Aticle in Chinese]. Wei WQ, Liang XQ, Wen XP. The association of mmp-1-1607(1G–2G) single nucleotide polymorphism with the susceptibility to non-small cell lung carcinoma in Guizhou Han nationality. J Guiyang Med College. 2007;32:267–72 [Aticle in Chinese].
27.
Zurück zum Zitat Cheng XL. Correlation of single nucleotide polymorphism in the matrix metalloproteinase-1 promoter(−1607) 1G/2G with risk of lung cancer. J Shanxi Med Univ. 2007;38:777–9 [Article in Chinese]. Cheng XL. Correlation of single nucleotide polymorphism in the matrix metalloproteinase-1 promoter(−1607) 1G/2G with risk of lung cancer. J Shanxi Med Univ. 2007;38:777–9 [Article in Chinese].
28.
Zurück zum Zitat Zhang WQ, Lin H, Zhou YA, Wang YJ, Cheng QS. Association of mmp-1-1607 1G/2G single nucleotide polymorphism with susceptibility to lung cancer in northwestern Chinese population of Han nationality. Chin J Med Genet. 2006;23:313–5 [Article in Chinese]. Zhang WQ, Lin H, Zhou YA, Wang YJ, Cheng QS. Association of mmp-1-1607 1G/2G single nucleotide polymorphism with susceptibility to lung cancer in northwestern Chinese population of Han nationality. Chin J Med Genet. 2006;23:313–5 [Article in Chinese].
29.
Zurück zum Zitat Su L, Zhou W, Asomaning K, Lin X, Wain JC, Lynch TJ, Liu G, Christiani DC. Genotypes and haplotypes of matrix metalloproteinase 1, 3 and 12 genes and the risk of lung cancer. Carcinogenesis. 2006;27:1024–9.PubMedCrossRef Su L, Zhou W, Asomaning K, Lin X, Wain JC, Lynch TJ, Liu G, Christiani DC. Genotypes and haplotypes of matrix metalloproteinase 1, 3 and 12 genes and the risk of lung cancer. Carcinogenesis. 2006;27:1024–9.PubMedCrossRef
30.
Zurück zum Zitat Fang S, Jin X, Wang R, Li Y, Guo W, Wang N, Wang Y, Wen D, Wei L, Zhang J. Polymorphisms in the mmp1 and mmp3 promoter and non-small cell lung carcinoma in north China. Carcinogenesis. 2005;26:481–6.PubMedCrossRef Fang S, Jin X, Wang R, Li Y, Guo W, Wang N, Wang Y, Wen D, Wei L, Zhang J. Polymorphisms in the mmp1 and mmp3 promoter and non-small cell lung carcinoma in north China. Carcinogenesis. 2005;26:481–6.PubMedCrossRef
31.
Zurück zum Zitat Schabath MB, Delclos GL, Martynowicz MM, Greisinger AJ, Lu C, Wu X, Spitz MR. Opposing effects of emphysema, hay fever, and select genetic variants on lung cancer risk. Am J Epidemiol. 2005;161:412–22.PubMedCrossRef Schabath MB, Delclos GL, Martynowicz MM, Greisinger AJ, Lu C, Wu X, Spitz MR. Opposing effects of emphysema, hay fever, and select genetic variants on lung cancer risk. Am J Epidemiol. 2005;161:412–22.PubMedCrossRef
32.
Zurück zum Zitat Zhu Y, Spitz MR, Lei L, Mills GB, Wu X. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer Res. 2001;61:7825–9.PubMed Zhu Y, Spitz MR, Lei L, Mills GB, Wu X. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer Res. 2001;61:7825–9.PubMed
33.
Zurück zum Zitat Liu D, Guo H, Li Y, Xu X, Yang K, Bai Y. Association between polymorphisms in the promoter regions of matrix metalloproteinases (mmps) and risk of cancer metastasis: a meta-analysis. PLoS One. 2012;7:e31251.PubMedCrossRef Liu D, Guo H, Li Y, Xu X, Yang K, Bai Y. Association between polymorphisms in the promoter regions of matrix metalloproteinases (mmps) and risk of cancer metastasis: a meta-analysis. PLoS One. 2012;7:e31251.PubMedCrossRef
34.
Zurück zum Zitat Peters J, Mengersen K. Selective reporting of adjusted estimates in observational epidemiology studies: reasons and implications for meta-analyses. Eval Health Prof. 2008;31:370–89.PubMedCrossRef Peters J, Mengersen K. Selective reporting of adjusted estimates in observational epidemiology studies: reasons and implications for meta-analyses. Eval Health Prof. 2008;31:370–89.PubMedCrossRef
35.
Zurück zum Zitat Li Y, Qiu LX, Shen XK, Lv XJ, Qian XP, Song Y. A meta-analysis of tp53 codon 72 polymorphism and lung cancer risk: evidence from 15,857 subjects. Lung Canc-J IASLC. 2009;66:15–21.CrossRef Li Y, Qiu LX, Shen XK, Lv XJ, Qian XP, Song Y. A meta-analysis of tp53 codon 72 polymorphism and lung cancer risk: evidence from 15,857 subjects. Lung Canc-J IASLC. 2009;66:15–21.CrossRef
Metadaten
Titel
MMP1-1607 1G/2G polymorphism and lung cancer risk: a meta-analysis
verfasst von
Xu-Yang Xiao
Xiao-Dong Wang
Dong-Yu Zang
Publikationsdatum
01.12.2012
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 6/2012
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-012-0502-4

Weitere Artikel der Ausgabe 6/2012

Tumor Biology 6/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.